Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Bank of America reduced its price target for Dell Technologies to $135 from $150, while maintaining a Buy rating. The cut reflects a sharp rise in memory prices that the bank says could materially pressure Dell's margins and fiscal 2027 earnings, though analysts caution the projected impacts are upper-bound estimates and may be mitigated by cost an…
Prada's reported purchase of Versace and progress on tech collaborations have rattled the stock but the deal size (~$1.375B) is under 10% of Prada's $14.1B market cap and should be manageable. Technicals and margin tailwinds leave room for a mid-term bounce toward $14. A disciplined entry at $11.00 with a $9.90 stop and a $14.00 target provides a d…
Catherine A. Gridley, executive vice president and A&D Sector President at TTM Technologies Inc, sold 20,000 shares on February 20, 2026, for $2.12 million. The company reported fourth-quarter 2025 results that beat analyst expectations on both non-GAAP EPS and net sales, yet the stock fell in aftermarket trading. InvestingPro valuation metrics cit…
Piper Sandler has maintained an Overweight rating and a $16.00 price target on Ardelyx, Inc. (ARDX), highlighting momentum in Ibsrela sales and the company's updated fiscal guidance. Ardelyx confirmed fiscal 2026 product revenue ranges, reported strong trailing-twelve-month revenue and liquidity metrics, disclosed plans for a Phase 3 trial in chron…
Morgan Stanley increased its price target for Deere & Co. to $730 from $560 while keeping an Overweight rating, driven by upward revisions to earnings and operating income forecasts and model adjustments following first-quarter 2026 results. The firm cited tariff, currency and segment-specific margin changes in its updated outlook. Deere's recent q…
TD Cowen has reaffirmed a Buy rating and a $165.00 price target on GeneDx (NASDAQ: WGS), reiterating confidence in the company’s fiscal 2026 revenue plan while flagging investor attention on costs, margins and free cash flow. The call for detail comes as GeneDx guides to strong exome and genome volume growth and continues to be profitable on a net …
Piper Sandler raised its 12-month price target on Akamai Technologies to $97 from $89 while keeping a Neutral rating, citing outsized fourth-quarter 2025 results and sizable compute and infrastructure services contract wins. The firm highlighted investor concerns around required investments, lower ARR-to-capex dynamics and a normalization in the se…
Morgan Stanley raised its price target for The Vita Coco Co. Inc to $57 from $49 while keeping an Equalweight rating, after boosting its fiscal 2026 and 2027 adjusted EBITDA estimates by 11% and 12% respectively. The bank increased its valuation multiple and highlighted both likely promotional pressure in the back half of the year and expected gros…
Piper Sandler has maintained an Overweight rating and a $30 price target on Biohaven Pharma (BHVN) after updating its model to incorporate recent clinical program changes, including an FDA-cleared dosing adjustment in the pivotal RISE 2 focal epilepsy trial and initial clinical proof-of-concept data for the company’s extracellular protein degrader …
Lake Street Capital Markets raised its rating on Tandem Diabetes Care to Buy from Hold and set a $50.00 price target, citing the company’s deliberate move to a pharmacy distribution model as a catalyst for more predictable revenue, higher gross margins and meaningful free cash flow. Tandem reported stronger-than-expected fourth-quarter results driv…
Canaccord Genuity reiterated its Buy rating and left its $170 price objective unchanged on GeneDx (NASDAQ:WGS) after the company released fourth-quarter results showing 27% revenue growth and improved margins. GeneDx delivered revenue of $121.0 million for the quarter, modestly ahead of estimates, while reaffirming full-year 2026 guidance that impl…
Generate Biomedicines, Inc. filed to raise up to $425 million in an initial public offering on the Nasdaq under the symbol GENB. The company plans to offer 25 million shares at an expected price of $15.00 to $17.00 per share and has granted underwriters an option for an additional 3.75 million shares. Its lead candidate, GB-0895, entered Phase 3 do…
An independent legal analysis from Gunnercooke GmbH concludes that the SAL token qualifies as an "Other Crypto-Asset" under the EU Markets in Crypto-Assets Regulation (MiCAR) and that its privacy features do not create a legal bar under Article 76(3) to listing on MiCAR-authorised exchanges. The opinion says exchanges can identify holders and revie…
The Bank of Israel left its benchmark interest rate unchanged on Monday as recent days brought renewed geopolitical uncertainty linked to a potential confrontation with Iran. The monetary committee reiterated its policy objectives of price stability, support for economic activity and market stability, while data showed moderating inflation, solid f…
Piper Sandler raised its 12-month price target on Moderna Inc. to $69 from $63 and kept an Overweight rating, citing progress across the company’s vaccine pipeline and updated discounting assumptions. Shares have jumped significantly over six months, while analysts note upcoming regulatory milestones, Phase III readouts and a solid cash position th…
Novo Nordisk’s experimental obesity drug CagriSema underperformed Eli Lilly’s Zepbound in a direct comparison, prompting analysts to question Novo’s path to regain its early lead in the obesity drug market. Industry strategists say the trial result amplifies commercial uncertainty and could push investor attention to potential M&A moves to shore up…
Mexican officials reported that 25 members of the National Guard were killed in Jalisco state in attacks that followed the capture of Jalisco New Generation cartel leader Nemesio Oseguera, alias "El Mencho." A state attorney’s office official was also killed, and Defense Minister Ricardo Trevilla said information leading to the capture and death ca…
InnovAge (INNV) has been through litigation and volatility; recent moves suggest much of the bad news is already priced into the stock. Revenue growth and improving margins give a plausible path to upside, but high valuation multiples and regulatory sensitivity make this a medium-risk trade. Enter on weakness, size carefully, and use a defined stop…
Peter J. Wilkinson, Labcorp's SVP and Chief Accounting Officer, sold 666 shares on February 19, 2026, for $277.94 per share, totaling $185,108. The transaction was carried out under a Rule 10b5-1 plan. Labcorp's stock trades at $282.67, up 12.67% year-to-date and cited as undervalued by InvestingPro. The company reported a Q4 2025 EPS beat alongsid…
Jefferies downgraded Deere & Co to Underperform, arguing the stock's rally has priced in a full recovery in the agriculture cycle and elevated multiples. The broker set a $550 target tied to a 15x multiple on what it expects to be peak earnings in 2029, and highlighted weakening farmer incomes, falling high-horsepower equipment sales, and persisten…
Stephens increased its price objective for AvidBank Holdings Inc. to $35 from $30 and kept an Overweight rating after the bank reported fourth-quarter operating results that fell short of analyst estimates on EPS but showed robust loan and deposit growth. The broker highlighted expected net interest margin expansion in the coming quarter and raised…
Piper Sandler increased its 12-month price target for Bristol-Myers Squibb to $75 from $66 and reiterated an Overweight rating, pointing to two principal paths the company could use to return to top-line growth after U.S. loss of exclusivity for Eliquis in 2028: a successful milvexian outcome in the LIBREXIA AF atrial fibrillation trial and progres…
Stephens reduced its price target on Zscaler to $225 from $340 but kept an Overweight rating, citing compressed software multiples and a more conservative target multiple of roughly 8.5 times enterprise value to forward revenue. The firm expects solid fiscal Q2 2026 results to act as a potential catalyst, while noting that sustaining 20%+ organic g…
Bank of America defended Blue Owl, saying market misinformation and elevated uncertainty have depressed the stock and created an attractive entry point. The bank set a $24 price target - more than a 100% total-return upside from current levels - based on a 25-times multiple on its 2028 distributable earnings estimate after adjusting for stock-based…
Stifel has reduced its 12-month price target for Now Inc (DNOW) to $16 from $18 while keeping a Buy rating. The firm pointed to ongoing ERP implementation headwinds at MRC Global's U.S. operations, which contributed to a fourth-quarter 2025 earnings and revenue shortfall and led management to delay guidance for 2026. The disruption affects roughly …
